Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with Chemoradiotherapy in Limited Stage SCLC
NCT06371482Phase 2Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Jun 2023
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in small cell lung cancer (SCLC), sponsored by The Fourth Hospital of Hebei Medical University. Started Jun 2023; status: recruiting.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06371482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06371482.